<DOC>
	<DOCNO>NCT02885766</DOCNO>
	<brief_summary>A multicenter , open label cohort Phase 1 dose find study evaluate tolerability , safety , pharmacokinetics preliminary efficacy PF-114 oral administration adult patient Philadelphia chromosome positive ( Ph+ ) chronic myeloid leukemia ( CML ) , resistant 2-nd generation Bcr-Abl inhibitor T315I mutation BCR-ABL gene .</brief_summary>
	<brief_title>Study Evaluate Tolerability , Safety , Pharmacokinetics Preliminary Efficacy PF-114 Oral Administration Adults With Ph+ Chronic Myeloid Leukemia , Which Resistant 2-nd Generation Bcr-Abl Inhibitors Has T315I Mutation BCR-ABL Gene</brief_title>
	<detailed_description>PF-114 low molecular inhibitor Bcr-Abl kinase activity , active respect native mutate form enzyme mutation Abl kinase domain . Preclinical vitro vivo study demonstrate ability PF-114 inhibit wild Bcr-Abl type T315I mutation , well kinds Bcr-Abl mutation kinase domain , include combined mutation . In contrast ponatinib , PF-114 develop increase action selectivity respect Bcr-Abl , potentially increase safety drug application people . The result perform preclinical study confirm improved selectivity PF-114 action respect Bcr-Abl kinase compare ponatinib . Indication : Adult patient Ph+ CML chronic phase ( CP ) accelerate phase ( AP ) resistant previous treatment least one 2-nd generation inhibitor Bcr-Abl ( dasatinib , nilotinib , bosutinib ) intolerant approve Bcr-Abl inhibitor T315I mutation BCR-ABL gene</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>Patients must meet follow criterion order eligible participation study : 1 . Able give write informed consent ; 2 . Male female patient ≥ 18 year old ; 3 . Confirmed diagnosis CML chronic accelerate phase accord European LeukemiaNet guideline 2013 ; 4 . Available information regard resistance therapy least one 2nd generation BcrAbl inhibitor ( dasatinib nilotinib bosutinib ) , intolerance approve BcrAbl inhibitor , presence T315I mutation irrespective treatment history ; 5 . In case previous history blast crisis phase CML least 6 month require pass end blast crisis phase first dose PF114 ; 6 . ECOG performance status ≤ 2 ( see Appendix 2 ) ; 7 . Adequate renal function define serum creatinine ≤ 1.5 time upper limit normal ( ULN ) ; 8 . Adequate hepatic function defy : serum bilirubin ≤ 1.5 X ULN unless patient diagnose Gilbert 's syndrome ; serum aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 X ULN ; alkaline phosphatase ≤ 2.5 X ULN ; INR ≤ 1.5 X ULN ; 9 . Adequate cardiac function define LVEF &gt; 40 % echocardiogram ; 10 . QTcF &lt; 470 m ; 11 . Patient recover ( Grade 1 less accord NCI CTCAE V 4.0 ) toxicity ( exclude alopecia ) associate prior treatment ; 12 . Female patient childbearing potential male patient female partner childbearing potential must agree abstinence sexual relation use effective method contraception throughout participation study ; 13 . Ability comply study procedure Investigator 's opinion . Patients must meet follow criterion order eligible participation study : 1 . Use follow previous therapy : 1. chemotherapy ≤ 21 day ( except hydroxyurea washout require ) prior first dose PF114 mesylate ; оr nitrosoureas оr mitomycin С ≤ 42 day prior first dose PF114 mesylate ; 2. approve tyrosine kinase inhibitor investigational agent ≤ 4 day prior first dose PF114 ; 3. radiotherapy ≤ 28 day prior first dose PF114 ; 4. autologous оr allogeneic stem сеll transplant &lt; 90 day prior enrollment ; 2 . Significant uncontrolled cardiac disease ; 3 . Sustained uncontrolled hypertension ≥ Grade 2 ( accord NCI CTC AE v4 ) ; 4 . Patient take medicinal product know prolong QT interval electrocardiogram , unless absolutely necessary opinion investigator ; 5 . Evidence ongoing graft versus host disease ( GVHD ) , GVHD require immunosuppressive therapy . Patients immunosuppressive therapy prophylaxis and/or treatment least 14 day prior first dose PF114 ; 6 . Major surgery within 35 day prior enrollment ; 7 . Uncontrolled intercurrent illness include , limited following : active systemic infection , uncontrolled seizure disorder , psychiatric social circumstance would limit compliance study requirement misrepresent result study ; 8 . Patient unable swallow study drug gastrointestinal disorder could negatively affect oral absorption PF114 ; 9 . Any malignancy CML within past 3 year ( except nonmelanoma skin cancer cervical cancer situ ) . 10 . Pregnancy breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>CML</keyword>
	<keyword>Myeloid leukaemia chronic</keyword>
	<keyword>CML progression</keyword>
	<keyword>Chronic phase chronic myeloid leukemia</keyword>
	<keyword>PF-114</keyword>
	<keyword>Cytogenetic response CCyR</keyword>
	<keyword>Major molecular response MMR</keyword>
	<keyword>Complete molecular response CMR</keyword>
	<keyword>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</keyword>
	<keyword>2-nd generation Bcr-Abl inhibitor resistant</keyword>
</DOC>